Ursodeoxycholic acid (UDCA) has for several years been used for the treatment of primary biliary cirrhosis (PBC). In PBC it is the only drug approved by the United States Food and Drug Administration, and recommended by the American Association for the Study of Liver Disease and the European Association for the Study of the Liver. Use of UDCA in patients with primary sclerosing hepatitis has been associated with improvements in serum liver tests and often also histological and clinical findings. Non-alcoholic fatty liver disease is the most common form of chronic hepatitis. Ursodeoxycholic acid showed in some studies beneficial effects on activity of aminotransferase as well as histopathological changes in the liver, but in another one no such improvement was observed. The best results were obtained with a higher dose of UDCA, and in combination with other drugs.